Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany.
Eur Neurol. 2012;67(3):162-6. doi: 10.1159/000334722. Epub 2012 Jan 20.
Immunomodulating therapies may prevent relapses in multiple sclerosis and stabilize neurological status. However, little is known about the influence particularly of newer drugs on cognitive functions. We conducted an open-label prospective study to demonstrate whether natalizumab is apt to improve cognitive functions and mood in 29 patients tested psychometrically while under treatment for 6 months. We found improvements in some measures of attention, memory, mood, and well-being, but no deterioration, although patients suffered from their diseases for more than 10 years and had an EDSS score of 3.5. It is concluded that natalizumab is able to stabilize or improve cognition and mood even in longer-lasting multiple sclerosis.
免疫调节疗法可能预防多发性硬化症的复发并稳定神经功能。然而，关于新型药物对认知功能的影响知之甚少。我们进行了一项开放标签的前瞻性研究，旨在证明那他珠单抗是否能够改善 29 名接受治疗 6 个月的患者的认知功能和情绪，这些患者通过心理测试进行了测试。我们发现注意力、记忆、情绪和幸福感等方面的一些指标有所改善，但没有恶化，尽管患者的疾病已经超过 10 年，并且 EDSS 评分为 3.5。研究结论是，那他珠单抗即使在持续时间更长的多发性硬化症中也能够稳定或改善认知和情绪。
